NCT04958187Unknown1 期
An Open Label, Single-Dose Study to Evaluate the Safety and Pharmacokinetics of ANG-3777 Injected Intravenously in Stable Adult Maintenance Hemodialysis Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Measure the pharmacokinetic (PK) parameters of a single dose of ANG-3777 including, but not limited to: Tmax
研究概览
简要总结
The purpose of this study is to evaluate the pharmacokinetics and safety of a single-dose of ANG-3777 in subjects with renal failure receiving maintenance hemodialysis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult male or female subjects, 18 to 75 years of age at time of informed consent who have been on maintenance HD 3 times a week for at least 3 months prior to signing informed consent.
- •Must receive HD 3 times a week.
- •Target post-dialysis body weight < 125 kg.
- •Have laboratory parameters at Screening as follows:
- •Serum albumin ≥ 3.0 g/dL
- •Blood hemoglobin ≥ 9.0 g/dL
- •Serum liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) < 2× the upper limit of normal
- •Have adequate single pool urea (Kt/V ≥ 1.2) for the 2 consecutive readings in the months preceding the Screening Visit.
- •Subjects will not be allowed to start any new medications during the study period (i.e., from treatment assignment to the follow-up visit) except in case of a medical emergency (the subject may be removed from the study accordingly as decided by the Principal Investigator [PI] and sponsor).
- •Subjects should be on stable doses of medications for at least 2 weeks preceding check-in to the research unit except medications used to manage co-morbidities associated with dialysis, e.g., Epogen, vitamin D analogs, and Venofer.
- •Women of childbearing potential will not be breast feeding and must have a negative serum pregnancy test at Screening and Day -
- •Women of childbearing potential must use 2 forms of effective birth control (at least one barrier method) during the study and for 31 days after end of infusion. Men will be required to use condoms for the duration of study and for 7 days after study discharge.
- •In the opinion of the investigator, the subject is capable of understanding and complying with the protocol. Subjects must have signed and dated the ICF prior to performance of any study related procedure including Screening procedures.
- •Must be receiving HD via an arterio-venous fistula or an arterio-venous graft with no access procedure performed within 1 month prior to receiving study drug.
排除标准
- •Subjects treated with the cytochrome P450 1A2 (CYP1A2) inhibitors ciprofloxacin (Cipro®) or fluvoxamine (Luvox®) within 14 days prior to anticipated first dose of study medication.
- •Ongoing infections or the use of anti-infective medications within 2 weeks prior to Screening.
- •History of previous organ transplant or known liver disease.
- •Have ongoing drug abuse/dependence (including alcohol) or recent history (within the past 5 years) of, or treatment for, alcohol or drug abuse.
- •Positive serum test for alcohol at Screening or on Day -
- •Positive drugs of abuse test at Screening (serum) or on Day -1 (saliva).
- •Current smokers who smoke > 5 cigarettes a day (serum cotinine levels ≥ 10 ng/mL) are excluded. Note: Cotinine is tested at Screening only. Every effort should be made to recruit nonsmokers; at least 8 subjects in this study should be nonsmokers.
- •Subjects with an active malignancy, suspicion of active malignancy by history or physical examination, or history of solid, metastatic, or hematologic malignancy with the exception of basal or squamous cell carcinoma of the skin that has been removed.
研究组 & 干预措施
ANG-3777
Experimental
Administered IV as a single dose over 30 minutes on Day 1, greater than 24 hours before receiving scheduled hemodialysis (HD).
干预措施: ANG-3777 (Drug)
结局指标
主要结局
Measure the pharmacokinetic (PK) parameters of a single dose of ANG-3777 including, but not limited to: Tmax
时间窗: Day 1 and Day 2
Measure the pharmacokinetic (PK) parameters of a single dose of ANG-3777 including, but not limited to: AUC(0-last) and AUC(0-inf)
时间窗: Day 1 and Day 2
Measure the pharmacokinetic (PK) parameters of a single dose of ANG-3777 including, but not limited to: Cmax
时间窗: Day 1 and Day 2
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetics of Everolimus in Subjects With Hepatic InsufficiencyHepatic InsufficiencyNCT00968591Novartis Pharmaceuticals34
招募中
早期 1 期
Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry DiseaseFabry DiseaseNCT06207552Children's Hospital of Fudan University6
已完成
1 期
MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)Human Immunodeficiency VirusNCT05494736Merck Sharp & Dohme LLC20
已完成
1 期
A Study to Evaluate the Pharmacokinetics of HSK7653 in Subjects With Renal ImpairmentRenal ImpairmentNCT05497297Haisco Pharmaceutical Group Co., Ltd.42
已完成
1 期
Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)End-Stage Renal Disease (ESRD)End-Stage Kidney Disease (ESKD)Kidney Failure, ChronicNCT05769595Merck Sharp & Dohme LLC17